4
|
Laucyte-Cibulskiene A, Ward LJ, Ebert T, Tosti G, Tucci C, Hernandez L, Kautzky-Willer A, Herrero MT, Norris CM, Pilote L, Söderberg M, Brismar TB, Ripsweden J, Stenvinkel P, Raparelli V, Kublickiene K. Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality. Biol Sex Differ 2021; 12:50. [PMID: 34526107 PMCID: PMC8444580 DOI: 10.1186/s13293-021-00393-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 08/29/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Sex differences are underappreciated in the current understanding of cardiovascular disease (CVD) in association with chronic kidney disease (CKD). A hallmark of CKD is vascular aging that is characterised, amongst others, by; systemic inflammation, microbiota disbalance, oxidative stress, and vascular calcification-features linked to atherosclerosis/arteriosclerosis development. Thus, it is the necessary to introduce novel biomarkers related to athero-/arteriosclerotic damage for better assessment of vascular ageing in patients CKD. However, little is known about the relationship between uraemia and novel CVD biomarkers, such as growth differentiation factor-15 (GDF-15), cartilage glycoprotein-39 (YKL-40) and matrix metalloproteinase-9 (MMP-9). Therefore, we hypothesise that there are sex-specific relationships between GDF-15, YKL-40, MMP-9 levels in end-stage kidney disease (ESKD) patients in relation to gut microbiota, vascular calcification, inflammation, comorbidities, and all-cause mortality. METHODS ESKD patients, males (n = 151) and females (n = 79), not receiving renal replacement therapy were selected from two ongoing prospective ESKD cohorts. GDF-15, YKL-40 and MMP9 were analysed using enzyme-linked immunosorbent assay kits. Biomarker levels were analysed in the context of gut microbiota-derived trimethylamine N-oxide (TMAO), vascular calcification, inflammatory response, oxidative stress, comorbidities, and all-cause mortality. RESULTS Increased GDF-15 correlated with higher TMAO in females only, and with higher coronary artery calcification and IL-6. In females, diabetes was associated with elevated GDF-15 and MMP-9, whilst males with diabetes only had elevated GDF-15. No associations were found between biomarkers and CVD comorbidity. Deceased males and females had higher GDF-15 concentrations (p = 0.01 and p < 0.001, respectively), meanwhile only YKL-40 was increased in deceased males (p = 0.02). CONCLUSIONS In conclusion, in males GDF-15 and YKL-40 were related to vascular calcification, inflammation, and oxidative stress, whilst in females GDF-15 was related to TMAO. Increased levels of YKL-40 and GDF-15 in males, and only GDF-15 in females, were associated with all-cause mortality. Our findings suggest that sex-specific associations of novel CVD biomarkers have a potential to affect development of cardiovascular complications in patients with ESKD.
Collapse
Affiliation(s)
- Agne Laucyte-Cibulskiene
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
- Department of Nephrology, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Liam J Ward
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Thomas Ebert
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Giulia Tosti
- Institute of Internal Medicine, Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
| | - Claudia Tucci
- Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy
| | - Leah Hernandez
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Alexandra Kautzky-Willer
- Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria
| | - Maria-Trinidad Herrero
- Clinical and Experimental Neuroscience, Institutes for Aging Research and Bio-Health Research of Murcia, School of Medicine, University of Murcia, Murcia, Spain
| | - Colleen M Norris
- University of Alberta, Faculty of Nursing, Edmonton, AB, Canada
- Cardiovascular and Stroke Strategic Clinical Network, Alberta Health Services, Edmonton, AB, Canada
| | - Louise Pilote
- Division of Clinical Epidemiology, Research Institute of McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Magnus Söderberg
- Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Göteborg, Sweden
| | - Torkel B Brismar
- Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
- Department of Radiology, Karolinska University Hospital in Huddinge, Stockholm, Sweden
| | - Jonaz Ripsweden
- Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
- Department of Radiology, Karolinska University Hospital in Huddinge, Stockholm, Sweden
| | - Peter Stenvinkel
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Valeria Raparelli
- University of Alberta, Faculty of Nursing, Edmonton, AB, Canada
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy
| | - Karolina Kublickiene
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
- Division of Renal Medicine, Department for Clinical Science, Intervention & Technology, Karolinska University Hospital-Flemingsberg Campus, 14186, Stockholm, Sweden.
| |
Collapse
|
6
|
Wang Y, Shen G, Wang H, Yao Y, Sun Q, Jing B, Liu G, Wu J, Yuan C, Liu S, Liu X, Li S, Li H. Association of high sensitivity C-reactive protein and abdominal aortic aneurysm: a meta-analysis and systematic review. Curr Med Res Opin 2017; 33:2145-2152. [PMID: 28699805 DOI: 10.1080/03007995.2017.1354825] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVE To evaluate the association of high sensitivity C-reactive protein (hsCRP) with the presence of abdominal aortic aneurysm (AAA). METHODS Medline, Cochrane, Embase, and Google Scholar databases were searched until 22 June 2016 using the keywords predictive factors, biomarkers, abdominal aortic aneurysm, prediction, high sensitivity C-reactive protein, and hsCRP. Prospective studies, retrospective studies, and cohort studies were included. RESULTS Twelve case-control studies were included in the meta-analysis with a total of 8345 patients (1977 in the AAA group and 6368 in the control group). The pooled results showed that AAA patients had higher hsCRP value than the control group (difference in means = 1.827, 95% CI = 0.010 to 3.645, p = .049). Subgroup analysis found AAA patients with medium or small aortic diameter (<50 mm) had higher hsCRP plasma levels than the control group (difference in means = 1.301, 95% CI = 0.821 to 1.781, p < .001). In patients with large aortic diameter (≥50 mm), no difference was observed in hsCRP levels between the AAA and control groups (difference in means = 1.769, 95% CI = -1.387 to 4.925, p = .272). Multi-regression analysis found the difference in means of hsCRP plasma levels between AAA and control groups decreased as aortic diameter increased (slope = -0.04, p < .001), suggesting that hsCRP levels may be inversely associated with increasing aneurysm size. CONCLUSIONS Our findings suggest that hsCRP levels may possibly be used as a diagnostic biomarker for AAA patients with medium or small aortic diameter but not for AAA patients with large aortic diameter. The correlation between serum hsCRP level and AAA aneurysm is not conclusive due to the small number of included articles and between-study heterogeneity.
Collapse
Affiliation(s)
- Yunpeng Wang
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Guanghui Shen
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Haiyang Wang
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Ye Yao
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Qingfeng Sun
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Bao Jing
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Gaoyan Liu
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Jia Wu
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Chao Yuan
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Siqi Liu
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Xinyu Liu
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Shiyong Li
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| | - Haocheng Li
- a Department of Vascular Surgery , The First Affiliated Hospital of Harbin Medical University , Harbin , China
| |
Collapse
|
13
|
Boytard L, Spear R, Chinetti-Gbaguidi G, Acosta-Martin AE, Vanhoutte J, Lamblin N, Staels B, Amouyel P, Haulon S, Pinet F. Role of Proinflammatory CD68
+
Mannose Receptor
−
Macrophages in Peroxiredoxin-1 Expression and in Abdominal Aortic Aneurysms in Humans. Arterioscler Thromb Vasc Biol 2013; 33:431-8. [DOI: 10.1161/atvbaha.112.300663] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Ludovic Boytard
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Rafaelle Spear
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Giulia Chinetti-Gbaguidi
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Adelina E. Acosta-Martin
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Jonathan Vanhoutte
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Nicolas Lamblin
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Bart Staels
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Philippe Amouyel
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Stephan Haulon
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Florence Pinet
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| |
Collapse
|